Table 2. Grade III–IV haematological toxicities with 3-weekly triple chemotherapy with docetaxel plus carboplatin plus epirubicin for up to six cycles (O'Neill et al, 2002).

	Neutropenia (% of patients)		Leucopenia (% of patients)		Thrombocytopenia (% of patients)		Anaemia (% of patients)
Cohort	Grade III	Grade IV	Grade III	Grade IV	Grade III	Grade IV	Grade III	Grade IV
1 (n=6)a	17	83	17	50	0	0	17	0
2 (n=6)b	0	100	0	100	17	33	17	0
3 (n=6)c	33	67	83	17	17	0	33	0
4 (n=3)d	0	100	0	67	0	0	0	0

^aDocetaxel 75 mg m⁻²+carboplatin to AUC 5 mg m⁻¹·min+epirubicin 50 mg m⁻².

^bDocetaxel 75 mg m⁻²+carboplatin to AUC 5 mg m⁻¹·min+epirubicin 60 mg m⁻².

^cDocetaxel 75 mg m⁻²+carboplatin to AUC 5 mg m⁻¹·min+epirubicin 50 mg m⁻² (day 8),

^dDocetaxel 75 mg m⁻²+carboplatin to AUC 4 mg m⁻¹·min+epirubicin 50 mg m⁻².

All drugs were given on day 1 of each cycle unless stated otherwise.